TrianglePersonalized neoantigen DNA vaccine (NCT03988283)
Personalized neoantigen DNA vaccine trial for Pediatric Recurrent Central Nervous System Tumors (NCT03988283). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
When a brain tumor returns in a teenager or young adult, or is a glioma that never truly goes away, options are few, and none are personal to that tumor.
The idea: read the tumor's own mutations, and write a vaccine against them.
At Washington University in St. Louis, the tumor tissue is sequenced and compared with the patient's normal DNA to find neoantigens, protein fragments made only by the cancer. Those are encoded into a DNA vaccine, delivered into muscle with a brief electrical pulse. Six monthly doses prime the response, then boosters every three months, to train T cells against that specific tumor.
A small first safety study, ages twelve to twenty-five. Michael Huang leads it. Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.
How these trials work: what Phase 1 actually is · common questions Not clinical evidence.